The benefit and risk of nivolumab in non-small-cell lung cancer: a single-arm meta-analysis of noncomparative clinical studies and randomized controlled trials

Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study

(2017) Matthew D Hellmann et al.   LANCET ONCOLOGY

Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial

(2017) Kevin J Harrington et al.   LANCET ONCOLOGY

First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer

(2017) David P. Carbone et al.   NEW ENGLAND JOURNAL OF MEDICINE

Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients

(2017) Guillermo De Velasco et al.   Cancer Immunology Research

Real-world data on nivolumab treatment of non-small cell lung cancer

(2016) O.T. Brustugun et al.   ACTA ONCOLOGICA

Efficacy and safety data from patients with advanced squamous NSCLC and brain metastases participating in the nivolumab Expanded Access Programme (EAP) in Italy

(2016) P. Bidoli et al.   ANNALS OF ONCOLOGY

Personalized PD-1/PD-L1 inhibitor therapy for advanced non small cell lung cancer beyond first line; a meta-analysis of potential predictive factors

(2016) O.M. Abdel-Rahman   ANNALS OF ONCOLOGY

Nivolumab in Combination With Platinum‐Based Doublet Chemotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer

(2016) Naiyer A. Rizvi et al.   JOURNAL OF CLINICAL ONCOLOGY

Nivolumab Monotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer

(2016) Scott Gettinger et al.   JOURNAL OF CLINICAL ONCOLOGY

The efficacy and safety of nivolumab in previously treated advanced non-small-cell lung cancer: a meta-analysis of prospective clinical trials

(2016) Jiaxing Huang et al.   OncoTargets and Therapy

Nivolumab, anti-programmed death-1 (PD-1) monoclonal antibody immunotherapy: Role in advanced cancers

(2016) Arun Rajan et al.   Human Vaccines & Immunotherapeutics

Nivolumab in the treatment of metastatic squamous non-small cell lung cancer: a review of the evidence

(2016) Joline S. J. Lim et al.   Therapeutic Advances in Respiratory Disease

PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?

(2016) Claud Grigg et al.   Journal for ImmunoTherapy of Cancer

Meta-analysis of incidence rate data in the presence of zero events

(2015) Matthew J Spittal et al.   BMC Medical Research Methodology

PD-1 Blockers

(2015) Jedd D. Wolchok   CELL

Preferred Reporting Items for a Systematic Review and Meta-analysis of Individual Participant Data

(2015) Lesley A. Stewart et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer

(2015) Scott N. Gettinger et al.   JOURNAL OF CLINICAL ONCOLOGY

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

(2015) Naiyer A Rizvi et al.   LANCET ONCOLOGY

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

(2015) Julie Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

(2015) Hossein Borghaei et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy

(2015) Ninh M. La-Beck et al.   PHARMACOTHERAPY

Ipilimumab in non-small cell lung cancer and small-cell lung cancer: new knowledge on a new therapeutic strategy

(2014) Erika Rijavec et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Phase II Study of Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in Patients with Advanced, Refractory Squamous Non-Small Cell Lung Cancer

(2014) S.S. Ramalingam et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) Maintenance as Monotherapy or in Combination With Bevacizumab (BEV) for Non-Small Cell Lung Cancer (NSCLC) Previously Treated With Chemotherapy

(2014) N.A. Rizvi et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Safety and Efficacy of First-Line Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) and Ipilimumab in Non-Small Cell Lung Cancer (NSCLC)

(2014) S.J. Antonia et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Cancer immunotherapies, their safety and toxicity

(2013) Gheath Alatrash et al.   Expert Opinion On Drug Safety

What future opportunities may immuno-oncology provide for improving the treatment of patients with lung cancer?

(2012) M. Reck   ANNALS OF ONCOLOGY

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape

(2012) J. M. Taube et al.   Science Translational Medicine

Hepatitis B and hepatitis C in Pakistan: prevalence and risk factors

(2008) Syed Asad Ali et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES